Harinarayanan Janakiraman
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA-Binding Proteins | 2 | 2018 | 215 | 1.120 |
Why?
|
| Pancreatic Neoplasms | 2 | 2022 | 332 | 0.870 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 163 | 0.780 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 75 | 0.740 |
Why?
|
| Precision Medicine | 1 | 2020 | 111 | 0.710 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 54 | 0.640 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 560 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 467 | 0.600 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 160 | 0.590 |
Why?
|
| Caspase 3 | 1 | 2016 | 233 | 0.590 |
Why?
|
| MicroRNAs | 2 | 2018 | 447 | 0.590 |
Why?
|
| Models, Biological | 1 | 2020 | 980 | 0.560 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 384 | 0.560 |
Why?
|
| Mouth Neoplasms | 1 | 2016 | 206 | 0.520 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 624 | 0.420 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2011 | 44 | 0.410 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 84 | 0.400 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 98 | 0.340 |
Why?
|
| HIV Seropositivity | 1 | 2008 | 65 | 0.340 |
Why?
|
| Neoplasms | 2 | 2018 | 1660 | 0.340 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2007 | 14 | 0.330 |
Why?
|
| Candida albicans | 1 | 2007 | 38 | 0.320 |
Why?
|
| Candidiasis | 1 | 2007 | 39 | 0.320 |
Why?
|
| Peritonitis | 1 | 2007 | 46 | 0.320 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 698 | 0.310 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2007 | 37 | 0.310 |
Why?
|
| Kidney Diseases | 1 | 2008 | 307 | 0.280 |
Why?
|
| Mice | 5 | 2022 | 8453 | 0.260 |
Why?
|
| Animals | 7 | 2022 | 20811 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 756 | 0.230 |
Why?
|
| Heterografts | 2 | 2020 | 70 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 124 | 0.220 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 86 | 0.220 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 211 | 0.210 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 81 | 0.210 |
Why?
|
| Cetuximab | 1 | 2020 | 19 | 0.200 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.190 |
Why?
|
| Pancreas | 1 | 2021 | 225 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 104 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 78 | 0.190 |
Why?
|
| Fluorouracil | 1 | 2020 | 130 | 0.190 |
Why?
|
| Disease Models, Animal | 3 | 2022 | 2542 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 304 | 0.180 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 191 | 0.180 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2018 | 43 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 475 | 0.170 |
Why?
|
| Humans | 11 | 2022 | 68502 | 0.160 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2018 | 92 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 306 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 163 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 79 | 0.150 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 1848 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 361 | 0.140 |
Why?
|
| Insulin | 1 | 2018 | 617 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 231 | 0.130 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 1037 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 529 | 0.120 |
Why?
|
| Melanoma | 1 | 2016 | 335 | 0.110 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2011 | 4 | 0.110 |
Why?
|
| Retinal Dehydrogenase | 1 | 2011 | 10 | 0.110 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 18 | 0.110 |
Why?
|
| Hedgehog Proteins | 1 | 2011 | 38 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 138 | 0.100 |
Why?
|
| Heterozygote | 1 | 2011 | 174 | 0.100 |
Why?
|
| Mice, SCID | 1 | 2011 | 238 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 120 | 0.100 |
Why?
|
| Smoking | 1 | 2018 | 1449 | 0.100 |
Why?
|
| Transfection | 1 | 2011 | 782 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 498 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1085 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2018 | 2684 | 0.090 |
Why?
|
| Albuminuria | 1 | 2008 | 171 | 0.080 |
Why?
|
| Fluconazole | 1 | 2007 | 26 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 2264 | 0.080 |
Why?
|
| Kidney Glomerulus | 1 | 2008 | 155 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2008 | 182 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2007 | 108 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1173 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 163 | 0.080 |
Why?
|
| Biopsy | 1 | 2008 | 538 | 0.070 |
Why?
|
| Female | 5 | 2018 | 37990 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2008 | 1034 | 0.060 |
Why?
|
| Oleic Acid | 1 | 2021 | 40 | 0.050 |
Why?
|
| Culture Media | 1 | 2021 | 155 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 1026 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 135 | 0.050 |
Why?
|
| Middle Aged | 3 | 2018 | 21116 | 0.050 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2018 | 18 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 59 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2018 | 87 | 0.040 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2018 | 25 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2018 | 127 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2018 | 239 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 100 | 0.040 |
Why?
|
| Male | 3 | 2018 | 37252 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 135 | 0.040 |
Why?
|
| Adult | 2 | 2018 | 21373 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2016 | 489 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2018 | 1663 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1026 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 2356 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 1691 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 3702 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 2779 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2008 | 2 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7026 | 0.020 |
Why?
|
| Aged | 1 | 2018 | 14841 | 0.010 |
Why?
|